New PET tracer aims to spotlight immune cells in lung cancer
NCT ID NCT05933239
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a new radioactive imaging agent called 68GaNOTA-Anti-MMR VHH2. It is designed to attach to certain immune cells (macrophages) in non-small cell lung cancer tumors and make them visible on a PET scan. The study will involve 20 patients who are already scheduled for surgery to remove their tumor. Before surgery, they will receive an injection of the imaging agent and have a PET/CT scan. After surgery, the removed tumor tissue will be analyzed to see if the scan correctly identified the immune cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68GaNOTA-Anti-MMR-VHH2 (a radioactive imaging agent)
What this could lead to
If successful, this could lead to a better way to see certain immune cells in lung cancer tumors, helping doctors understand the tumor environment and potentially guide treatment decisions.
What could go wrong
This is a small, early-phase imaging study with only 20 participants. It is not designed to treat cancer, and the imaging agent may not reliably show the target cells in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitair Ziekenhuis Brussel
RECRUITINGJette, Brussels Capital, 1090, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••